
ASH 2020 VIRTUAL SCIENTIFIC PROGRAM
DECEMBER 5-8 , 2020

Bristol Myers Squibb

Compendium of presentations

Click on date to see a list of scheduled presentations

Table of Contents

Saturday,
December 5

Sunday,
December 6

Monday,
December 7

Publication
Only

Saturday, December 5

MULTIPLE MYELOMA

Oral Presentation

Presentation #131: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Lead Author and Presenter: Yi Lin, Mayo Clinic, Rochester, MN

Session: Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data

Time and Channel: 10:00AM, Channel: 10

Poster Presentations

Presentation #1358: Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001

Lead Author and Presenter: Michael Amatangelo, Bristol Myers Squibb, Princeton, NJ

Session: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

Presentation #1359: Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

Lead Author and Presenter: Michael Amatangelo, Bristol Myers Squibb, Princeton, NJ

Session: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

Presentation #1367: Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis

Lead Author and Presenter: Jesus Berdeja, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Session: Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Presentation #1378: Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Lead Author and Presenter: Ankit Kansagra, UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX,

Session: Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Presentation #1405: Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Lead Author*: Julie Rytlewski, Bristol Myers Squibb, Princeton, NJ

Session: Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Presentation #1418: KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Lead Author and Presenter: Saad Z. Usmani, Levine Cancer Institute, Charlotte, NC

Session: Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Presentation #1598: Healthcare Resource Utilization and Cost of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma Receiving the BCMA-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Trial

Lead Author and Presenter: Parameswaran Hari, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Session: Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I

Presentation #1603: Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Lead Author and Presenter: Noopur Raje, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA

Session: Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I

Presentation #1653: A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for idecabtagene vicleucel (ide-cel, bb2121), a BCMA Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Lead Author and Presenter: Nina Shah, University of California, San Francisco, CA

Session: Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

NON-HODGKIN LYMPHOMA

Oral Presentation

Presentation #118: Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucl in TRANSCEND NHL 001

Lead Author and Presenter: Maria Lia Palomba, Memorial Sloan Kettering Cancer Center, New York, NY

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma Clinical Trials

Time and Channel: 9:45AM, Channel: 7

Poster Presentations

Presentation #1123: Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R² Followed By Maintenance

Lead Author and Presenter: Morton Coleman, Clinical Research Alliance Inc., Weill Cornell Medicine, New York, NY

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Presentation #1196: Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucl (liso-cel) in the Nonuniversity Setting: Initial Results from the OUTREACH Study

Lead Author and Presenter: John E. Godwin, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR

Session: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

ACUTE MYELOID LEUKEMIA

Oral Presentations

Presentation #111: Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Lead Author and Presenter: Hartmut Döhner, Ulm University Hospital, Ulm, Germany

Session: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML

Time and Channel: 9:30AM, Channel: 12

Presentation #214: Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial

Lead Author and Presenter: Gail J. Roboz, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY

Session: Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management And Outcome

Time and Channel: 12:15PM, Channel: 4

Poster Presentations

Presentation #1008: Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Lead Author and Presenter: Dirk Reinhardt, Department of Pediatric Hematology and Oncology, Essen University Hospital, Essen, Germany

Session: Acute Myeloid Leukemia: Clinical Studies: Poster I

Presentation #1036: CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Lead Author and Presenter: Andrew Wei, Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia

Session: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

MYELOYDYSPLASTIC SYNDROME

Poster Presentations

Presentation #1611: Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study

Lead Author and Presenter: Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrinò Morelli, Reggio Calabria, Italy

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

Presentation #1617: Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect[®] MDS/AML Disease Registry

Lead Author and Presenter: Tracy I. George, ARUP Laboratories, Salt Lake City, UT

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

ANEMIA β -THALASSEMIA

Poster Presentations

Presentation #777: Rapamycin (Sirolimus) and RAP-536 Increase Red Blood Cell Parameters through Distinct Mechanisms in Wild-Type and Thalassemic Mice

Lead Author*: Melih Acar, Formerly Bristol Myers Squibb, Princeton, NJ

Session: Session: Thalassemia and Globin Gene Regulation: Poster I

Presentation #779: RAP-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia

Lead Author*: Melih Acar, Formerly Bristol Myers Squibb, Princeton, NJ

Session: Session: Thalassemia and Globin Gene Regulation: Poster I

Sunday, December 6

MULTIPLE MYELOMA

Oral Presentation

Presentation #437: Secondary Quality of Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the BCMA-Directed CAR T cell therapy Idecabtagene Vicleucef (ide-cel, bb2121): Results from the KarMMa Clinical Trial

Lead Author and Presenter: Nina Shah, University of California, San Francisco, CA

Session: Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma

Time and Channel: 12:15PM, Channel: 11

Poster Presentations

Presentation #2295: Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel CELMoD Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Lead Author and Presenter: Lilly Wong, Bristol Myers Squibb, Princeton, NJ

Session: Myeloma: Therapy, excluding Transplantation: Poster II

Presentation #2314: Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Lead Author*: David S. Siegel, Division of Multiple Myeloma, Hackensack University Medical Center, Hackensack, NJ

Session: Myeloma: Therapy, excluding Transplantation: Poster II

Presentation #2315: Idecabtagene Vicleucef (ide-cel, bb2121) Responses Are Characterized by Early and Temporally Consistent Activation and Expansion of CAR T Cells With a T Effector Phenotype

Lead Author and Presenter: Nathan Martin, Bristol Myers Squibb, Princeton, NJ

Session: Myeloma: Therapy, excluding Transplantation: Poster II

Presentation #2323: KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucef (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Lead Author and Presenter: Michel Delforge, Department of Hematology, University Hospital Leuven, Leuven, Belgium

Session: Myeloma: Therapy, excluding Transplantation: Poster II

Presentation #2350: Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucl (orva-cel; JCARH125) in the Phase 1/2 EVOLVE Study

Lead Author*: Julia Piasecki, Bristol Myers Squibb, Seattle, WA

Session: Immunotherapies: Poster II

Presentation #2358: Orvacabtagene Autoleucl (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized by a Predominant Central Memory Phenotype with High In Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Lead Author and Presenter: Lucrezia Colonna, Bristol Myers Squibb, Seattle, WA

Session: Cell Collection and Processing: Poster II

HODGKIN LYMPHOMA

Oral Presentation

Presentation #471: Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Lead Author and Presenter: Christopher A. Yasenach, Willamette Valley Cancer Institute and Research Center, Eugene, OR

Session: Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma

Time and Channel: 2:15PM Channel: 7

NON-HODGKIN LYMPHOMA

Oral Presentation

Presentation #340: Subgroup Analyses of Elderly Patients Aged ≥ 70 years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R² Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Lead Author and Presenter: Frederick Lansigan, Dartmouth–Hitchcock Medical Center, Lebanon, NH

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia

Time and Channel: 10:30AM, Channel: 8

Poster Presentations

Presentation #2045: Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Lead Author*: Armando Santoro, Humanitas Clinical and Research Center IRCCS, Humanitas University, Milano, Italy

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Presentation #2116: Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lead Author*: David G. Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA

Session: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II

Presentation #2514: Costs of Postinfusion Monitoring by Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH Trials

Lead Author and Presenter: Maria Lia Palomba, Memorial Sloan Kettering Cancer Center, New York, NY

Session: Health Services Research—Malignant Conditions (Lymphoid Disease): Poster II

Presentation #2565: Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Lead Author and Presenter: Tanya Siddiqi, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

Session: Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II

ACUTE MYELOID LEUKEMIA

Poster Presentations

Presentation #1912: Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death

Lead Author and Presenter: Andrew J. Klink, Cardinal Health Specialty Solutions, Dublin, OH

Session: Acute Myeloid Leukemia: Clinical Studies: Poster II

Presentation #1917: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Lead Author and Presenter: Farhad Ravandi, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Session: Acute Myeloid Leukemia: Clinical Studies: Poster II

Presentation #2523: Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect[®] MDS/AML Disease Registry

Lead Author and Presenter: Gail J. Roboz, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

Presentation #2527: Indirect Costs of Oral Versus Non-Oral Therapies in Hematologic Malignancies: A Systematic Literature Review

Lead Author and Presenter: Mir Sohail Fazeli, Evidinno Outcomes Research Inc., Vancouver, BC, Canada

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

MYELODYSPLASTIC SYNDROME

Poster Presentations

Presentation #2190: Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the MEDALIST Trial

Lead Author and Presenter: Uwe Platzbecker, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

Session: Myelodysplastic Syndromes—Clinical Studies: Poster II

Presentation #2198: The COMMANDS Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions

Lead Author and Presenter: Matteo Della Porta, Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy

Session: Myelodysplastic Syndromes—Clinical Studies: Poster II

ANEMIA β -THALASSEMIA

Oral Presentation

Presentation #364: Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the BELIEVE Trial

Lead Author and Presenter: Maria Domenica Cappellini, University of Milan, Milan, Italy

Session: Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease and Beta Thalassemia

Time and Channel: 9:30AM, Channel: 19

Poster Presentations

Presentation #1695: Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β -Thalassemia with Luspatercept: Longitudinal Results of the BELIEVE Trial

Lead Author and Presenter: Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center Raid El Solh, Beirut, Lebanon

Session: Thalassemia and Globin Gene Regulation: Poster II

Presentation #1697: Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β -Thalassemia in the BELIEVE Trial

Lead Author and Presenter: Olivier Hermine, Imagine Institute, INSERM U1163, University of Paris, Paris, France

Session: Thalassemia and Globin Gene Regulation: Poster II

MYELOFIBROSIS

Poster Presentation

Presentation #2518: Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Lead Author and Presenter: Francesco Passamonti, Department of Medicine and Surgery, University of Insubria, Varese, Italy

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

Monday, December 7

MULTIPLE MYELOMA

Oral Presentation

Presentation #724: First results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lead Author and Presenter: Neils Van De Donk, Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands

Session: Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis

Time and Channel: 1:30PM, Channel: 10

Poster Presentations

Presentation #3234: Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Lead Author and Presenter: Noopur Raje, Massachusetts General Hospital Cancer Center, Boston, MA

Session: Myeloma: Therapy, excluding Transplantation: Poster III

Presentation #3244: Clinical Features and Survival Outcomes in Diabetic Patients With Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect[®] MM Registry

Lead Author and Presenter: Lisa La, Mount Sinai Hospital, New York, NY

Session: Myeloma: Therapy, excluding Transplantation: Poster III

Presentation #3423: Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012–2017 Medicare Data

Lead Author and Presenter: Ruben Niesvizky, Multiple Myeloma Center, New York-Presbyterian/Weill Cornell Medical Center, New York, NY

Session: Health Services Research—Malignant Conditions (Lymphoid Disease): Poster III

Presentation #3465: Health State Utility Valuation in Patients with Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Treated with the BCMA-Directed CAR T Cell Therapy, Idecabtagene Vicleuceel (ide-cel, bb2121): Results from the KarMMa Trial

Lead Author and Presenter: Michel Delforge, Department of Hematology, University Hospital Leuven, Leuven, Belgium

Session: Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III

NON-HODGKIN LYMPHOMA

Poster Presentation

Presentation #2939: Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Lead Author and Presenter: Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France

Session: Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

ACUTE MYELOID LEUKEMIA

Oral Presentations

Presentation #621: CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Lead Author and Presenter: Esther Natalie Oliva, Division of Hematology, Azienda Ospedaliera (B-M-M), Bologna, Italy

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies

Time and Channel: 9:15AM, Channel: 14

Presentation #692: CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Lead Author and Presenter: Gail J. Roboz, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY

Session: Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches

Time and Channel: 2:30PM, Channel: 12

Poster Presentations

Presentation #2819: Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

Lead Author and Presenter: Clara Chen, Bristol Myers Squibb, Princeton, NJ

Session: Acute Myeloid Leukemia: Clinical Studies: Poster III

Presentation #2887: CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Lead Author*: Diana R. Dunshee, Formerly Bristol Myers Squibb, Princeton, NJ

Session: Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III

Presentation #3437: Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)

Lead Author*: Ashley Tabah, Bristol Myers Squibb, Princeton, NJ

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Presentation #3444: Economic Burden of Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Study Using the SEER-Medicare Database

Lead Author*: Ashley Tabah, Bristol Myers Squibb, Princeton, NJ

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Presentation #3488: Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment

Lead Author and Presenter: Tommi Tervonen, Evidera, London, United Kingdom

Session: Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA

Oral Presentations

Presentation #544: TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Lead Author and Presenter: William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX

Session: CLL: Therapy, excluding Transplantation

Time and Channel: 7:30AM, Channel: 9

Presentation #546: Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of TRANSCEND CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Lead Author and Presenter: Tanya Siddiqi, City of Hope National Medical Center, Duarte, CA

Session: CLL: Therapy, excluding Transplantation

Time and Channel: 8:00AM, Channel: 9

CHRONIC MYELOID LEUKEMIA

Poster Presentation

Presentation #3074: Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Lead Author and Presenter: Massimo Breccia, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy

Session: Chronic Myeloid Leukemia: Therapy: Poster III

MYELOYDYSPLASTIC SYNDROME

Poster Presentations

Presentation #3111: Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the MEDALIST Study

Lead Author and Presenter: Rami S. Komrokji, Moffitt Cancer Center, Tampa, FL

Session: Myelodysplastic Syndromes—Clinical Studies: Poster III

Presentation #3486: Real-World Assessment of Nationwide Health Economic Burden and Treatment-Based Survival for Current Myelodysplastic Syndromes Treatment Practice in Japan

Lead Author and Presenter: Saaya Tsutsu , Celgene K.K., a Bristol-Myers Squibb Company, Tokyo, Japan

Session: Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

Presentation #3492: Physicians' Experience in Blood Supply Shortages and the Top Factors That Impact the Clinical, Economic, and Humanistic Outcomes of Myelodysplastic Syndrome (MDS) Patients in 5 European Countries

Lead Author*: Shaloo Gupta, Kantar, New York, NY

Session: Outcomes Research—Malignant Conditions (Myeloid Disease): Poster III

MYELOFIBROSIS

Poster Presentations

Presentation #2992: Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) – Updated Data from the Phase 2 ACE-536-MF-001 Study

Lead Author and Presenter: Aaron T. Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Session: Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

Presentation #3006: Long-Term Safety of Fedratinib in Patients With Intermediate- or High-Risk Myelofibrosis (MF)

Lead Author and Presenter: Animesh Pardanani, Mayo Clinic of Rochester, Rochester, MN

Session: Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

Presentation #3442: Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with a Myelofibrosis Treated with First-Line Ruxolitinib

Lead Author*: Jonathan K. Kish, Cardinal Health, Dublin, OH

Session: Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Publication Only

ACUTE MYELOID LEUKEMIA

Publication #4347: Annual Healthcare Resource Utilization and Costs in U.S. Patients Diagnosed with Relapsed Acute Myeloid Leukemia

Lead Author: Ashley Tabah, Bristol Myers Squibb, Princeton, NJ

Publication #4351: A Systematic Literature Review of Disease Burden and Clinical Efficacy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Lead Author: Antonio Medina de Almeida, Hospital da Luz, Lisbon, Portugal

Publication #4354: Physicians' Perceptions and Use of IDH1/2 Mutational Testing and Treatment Selection Among Patients with Relapsed or Refractory Acute Myeloid Leukemia in Routine Clinical Practice

Lead Author: Andrew J. Klink, Cardinal Health Specialty Solutions, Dublin, OH

CHRONIC MYELOID LEUKEMIA

Publication #3963: A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

Lead Author: Kathryn Kolibaba, McKesson Life Sciences, McKesson, The Woodlands, TX

Publication #3966: Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Lead Author: Michael J. Mauro, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering, New York, NY

Publication #3969: Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Lead Author: Andrew J. Klink, Cardinal Health Specialty Solutions, Dublin, OH

MYELOUDYSPLASTIC SYNDROME

Publication #4346: Real-World Experience with Anemia and Iron Overload Therapies in Myelodysplastic Syndromes (MDS): Treatment Sequence, Duration, and Patient Compliance

Lead Author: Krystal Huey, Bristol Myers Squibb, Princeton, NJ

Publication #4418: Association between Transfusion Status (TS) and Clinical and Economic Outcomes in Patients with Myelodysplastic Syndromes (MDS) from the Physicians' Perspective

Lead Author: Austin Kulasekararaj, King's College Hospital - NHS Foundation Trust, NIHR Wellcome King's Clinical Research Facility, London and King's College London, London, United Kingdom